Can obstructive sleep apnea cause elevated hemoglobin and hematocrit?

Obstructive sleep apnea (OSA) is characterized by recurrent upper airway collapse that results in intermittent nocturnal hypoxia. This physiological stressor activates specific adaptive pathways designed to maintain oxygen delivery to tissues, primarily by increasing the production of red blood cells.

Clinical effectiveness and blood markers

The clinical presentation of elevated hemoglobin and hematocrit in response to OSA, often referred to as secondary polycythemia, is a well-documented phenomenon.

• Prevalence and severity: While mechanistically direct, the prevalence of overt polycythemia in the general OSA population is relatively low, approximately 2%. However, this increases to roughly 6% in patients with severe OSA.
• Predictive factors: Research indicates that the severity of nocturnal oxygen desaturation (mean SpO2) is a stronger independent predictor of elevated hemoglobin and hematocrit than the frequency of apnea events (AHI).
• Response to treatment: The initiation of Continuous Positive Airway Pressure (CPAP) therapy has been shown to reverse these effects. Studies have demonstrated a mean reduction in hemoglobin of approximately 3.76 g/L in patients following consistent CPAP use, as the underlying stimulus for excess red blood cell production is removed.

Mechanistic explanations

The link between desaturation events and blood marker changes is mediated by the body's highly sensitive oxygen-sensing apparatus.

• HIF signaling: Intermittent hypoxia during sleep triggers the stabilization of Hypoxia-Inducible Factors (HIF-1α and HIF-2α). These transcription factors translocate to the nucleus and bind to hypoxia-response elements (HREs) in the erythropoietin gene.
• EPO production: This signaling occurs primarily in the peritubular interstitial cells of the kidneys. The resulting increase in erythropoietin (EPO) synthesis and secretion stimulates erythroid progenitor cells in the bone marrow.
• Erythropoiesis: This cascade drives compensatory erythropoiesis, increasing the circulating red blood cell mass to enhance the blood's oxygen-carrying capacity. In chronic OSA, the magnitude of EPO elevation may be partially blunted by reoxygenation phases or systemic inflammation, but the underlying pathway remains the primary driver for elevated hematocrit levels.

Bottom line

Repeated nocturnal oxygen desaturations in OSA drive a clear physiological cascade: HIF-mediated signaling increases renal EPO production, which stimulates erythropoiesis and can manifest as elevated hemoglobin and hematocrit, particularly in patients with significant nocturnal hypoxemia.